van Santen DK, Agius PA, Sasadeusz J, et al. - In HIV/hepatitis C virus (HCV) co-infected individuals, markers of HIV disease severity are linked with with higher liver fibrosis, which may be reversed by HCV treatment. Researchers here examined people living with HIV for the impact of surrogate markers of HIV-infection and other determinants of liver stiffness prior to HCV treatment and changes after HCV cure. An HCV treatment implementation study seeking HCV micro-elimination among gay and bisexual men with HIV in Melbourne, Australia (co-EC Study) was used to obtain data for this study. Transient elastography (FibroScan) was used to determine liver stiffness measurements (LSM) before and after direct-acting antiviral treatment. One hundred seventy-three participants had at least one LSM available, and 98 participants had two LSMs available. Findings revealed low levels of liver stiffness before treatment initiation and a small reduction (6%) in LSM following HCV cure in people living with HIV. In this study, there appeared no clear predictors affecting change in LSM following cure, including markers of HIV infection. However, higher LSM values remained related, even after HCV was cured, with markers of advanced HIV immunodeficiency and hazardous alcohol consumption.